Highlights from CMSC 2024

Real-world Persistence and Adherence to Ofatumumab vs Ocrelizumab in Patients With Multiple Sclerosis

The real-world study comparing ofatumumab (OMB) and ocrelizumab (OCR) demonstrates comparable persistence and adherence between the two therapies. Specifically, 77% of patients on ofatumumab were adherent at 18 months, and 71% at 24 months, underscoring the convenience of ofatumumab as an at-home self-injectable therapy. This translates into high adherence and persistence, making it a reliable treatment option for multiple sclerosis patients.

Abstract →